Elevated Mitochondrial and Heme Function as Hallmarks for Non-Small Cell Lung CancersChantal Vidal, Sagar Sohoni and Li Zhang*
Department of Molecular and Cell Biology, Center for Systems Biology, University of Texas at Dallas
- *Corresponding Author:
- Li Zhang
Department of Molecular and Cell Biology
Centre for Systems Biology, University of Texas at Dallas
Mail Stop RL11, 800 W, Campbell Road
Richardson, TX 75080, USA
Tel: +1 972-883-2111
E-mail: [email protected], [email protected]
Received Date: July 04, 2016; Accepted Date: October 15, 2016; Published Date: October 18, 2016
Citation: Vidal C, Sohoni S, Zhang S (2016) Elevated Mitochondrial and Heme Function as Hallmarks for Non-Small Cell Lung Cancers. J Mol Biomark Diagn 7:305. doi: 10.4172/2155-9929.1000305
Copyright: © 2016 Vidal C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Many targeted therapies have been developed to treat lung cancer. Unfortunately, however statistical data over the past two decades suggest only a slight improvement in a patient's survival rate after diagnosis. Clonal evolution and tumor heterogeneity are the major obstacles in designing effective targeted treatments against cancer. To create more comprehensive treatments, emerging therapies target bioenergetic pathways of cancer cells. Like normal cells, cancer cells can generate energy only through glycolysis and oxidative phosphorylation. Notably, a number of studies have shown that many types of cancer cells rely heavily on mitochondrial respiration. Importantly, research carried out in the authors’ laboratory showed that non-small cell lung cancer cells exhibit increased levels of mitochondrial and heme function. Hence, limiting heme availability interferes with bioenergetics of cancer cells. Evidently, targeting heme function may provide an effective way for treating lung cancer.